Scott Norberg

Company: National Cancer Institute (NCI) in NIH

Job title: Head of Solid Tumor Therapy Group

Seminars:

Developing TCR-T cell Therapy for Patients with HIV and HPV-Associated Cancer: Extending a Promising Therapy to Underrepresented Groups 1:55 pm

• Adoptive T cell therapy shows promise but often excludes HIV-positive individuals from cancer trials. • Evidence suggests full-dose chemotherapy and immunotherapy are safe for HIV positive cancer patients. • Retrospective studies indicate comparable safety and efficacy of CD19 CAR T cell therapy in people with HIV and B-cell malignancies. • We aim to test…Read more

day: Conference Day Two

Developing TCR-T cell Therapy for Patients with HIV and HPV-Associated Cancer: Extending a Promising Therapy to Underrepresented Groups 2:00 pm

Adoptive T cell therapy shows promise but often excludes HIV-positive individuals from cancer trials. Evidence suggests full-dose chemotherapy and immunotherapy are safe for HIV-positive cancer patients. Retrospective studies indicate comparable safety and efficacy of CD19 CAR T cell therapy in people with HIV and B-cell malignancies. We aim to test the safety and efficacy of…Read more

day: DAY TWO TRACK 2 B

Critical Steps for Transitioning to Clinical Trials – Navigating Regulations & Pre-IND Studies 9:01 am

As the T-cell receptor (TCR) therapy landscape continues to expand, the challenges encountered in its development demand focused attention and collaborative strategies. This session explores regulatory complexities, safety imperatives, study design optimization, and resource constraints stands at the forefront of current TCR research and development. Join us as we delve into pivotal strategies aimed at…Read more

day: Pre-Conference Workshop Day